 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...4142434445464748495051...858859» |
- Bavencio (avelumab) / EMD Serono, navtemadlin (KRT-232) / Kartos Therap
Cutaneous Merkel cell carcinoma (MCC): updates from AAD Annual Congress 2024. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2909;
Relevant scientific progresses have been made in these years for a better knowledge of this rare skin cancer, particularly concerning its histopathological diagnosis and clinical management. However, further studies are necessary to characterize better refractory MCCs and to develop alternative treatment strategies for their care.**
- Revealing patient characteristics and treatment outcomes in ultra-long biologic users for psoriasis. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2738;
The median PASI around 2.5 throughout the 10 years treatment indicates that this value was an acceptable measure for patients and treating physicians. Remarkably, ultra-long use was reached also in patients having multiple comorbidities (including PsA) and a variety of dose adjustments of the biologics was applied.
- Enbrel (etanercept) / Pfizer, Amgen
A unique case of Etanercept-induced juvenile disabling pansclerotic morphea (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2719;
agents expands, it becomes crucial to recognize their potential AE. And given that cutaneous adverse reactions are among the most common AE encountered in patients receiving TNF- alpha inhibitors, as physicians and as dermatologists, we must maintain heightened vigilance
- Unlocking the Secrets of Psoriasis Treatment: Exploring the Impact of Blood Ratios on Treatment Success with Biological Agents in Psoriasis Vulgaris Patients (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2712;
It may be easier to obtain information about the course of the disease in a busy dermatology clinic with simple blood tests such as MPV, NLR and PLR. A cost-effective approach is taken when both the patients
- Journeying Through Evidence: Scoping the Revival of Anti-TNF Alpha in Psoriasis Treatment and Cardiovascular Risk Reduction (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2701;
could be considered earlier in the treatment algorithm, preceding anti-IL17 or IL23 agents. Further long-term studies are warranted to elucidate their precise cardiovascular effects and optimize treatment strategies in psoriasis management.
- Humira (adalimumab) / AbbVie
Experience with multiple non-medical switches between originator and biosimilars of adalimumab in patients with psoriasis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2679;
FIGURE 1. Survival plot visualising the number of patients within each subcohort at different time points.
- isotretinoin / Generic mfg.
Severe epidermal growth factor receptor inhibitors- induced papulo-pustular eruption with good response to low-dose isotretinoin and low-dose systemic corticotherapy (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2648;
Survival plot visualising the number of patients within each subcohort at different time points. We report the case of a 71 years old male patient, known with advanced colorectal cancer (extension to the upper bladder wall, multiple associated loco-regional adenopathies, multiple liver metastases) , under treatment with panitumumab, a humanized monoclonal antibody that inhibits EGFR...He was diagnosed with grade 3 papulopustular eruption secondary to epidermal growth factor receptor inhibitors treatments and recommended oral antibiotherapy with doxycycline 200 mg daily, topical low-potency corticosteroids along with general measures like avoidance of frequent washing with hot water using hard soaps, detergents, solvents, or disinfectants, limitation of sun exposure, usage of broad-spectrum sunscreen and emollients twice daily...Therefore, under the close surveillance of the liver tests and of the lipidogram, and with the oncologist
- Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Super response to an inconsistent administration of tildrakizumab in a biologic-na (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2639;
Moreover, tildrakizumab could potentially have a significant effect on lowering adipokine levels (resistin and leptin) in patients affected by psoriasis and obesity. Therefore, the selection of the optimal treatment based on various characteristics of patients with a particular condition should be personalized, rather than based solely on the disease itself.
- Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Humira (adalimumab) / AbbVie
Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 and Adalimumab Reference Product in Patients with Plaque Psoriasis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2470;
Results of this study demonstrated similarity for PK, efficacy, immunogenicity, and safety in patients with Ps switching 3 times between adalimumab RP and ABP 501 as compared to patients receiving continued use of adalimumab RP. These results support a demonstration of interchangeability between ABP 501 and adalimumab RP.
- rocatinlimab (KHK4083) / Amgen
Study design of phase 3 trials evaluating rocatinlimab efficacy and safety in moderate-to-severe atopic dermatitis: the ROCKET program (Open Stage) - Aug 5, 2024 - Abstract #EADV2024EADV_2438;
P3
These results support a demonstration of interchangeability between ABP 501 and adalimumab RP. The comprehensive ROCKET phase 3 program will allow robust investigation of the efficacy and long-term safety of rocatinlimab in adults and adolescents with msAD.
- rocatinlimab (KHK4083) / Amgen
Study Design of Phase 3 Trials Evaluating Rocatinlimab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis: the ROCKET Program (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2136;
P3
The comprehensive ROCKET phase 3 program will allow robust investigation of the efficacy and long-term safety of rocatinlimab in adults and adolescents with msAD. The comprehensive ROCKET phase 3 program will allow robust investigation of the efficacy and long-term safety of rocatinlimab in adults and adolescents with msAD.
- Remicade (infliximab) / J&J
Infliximab in the Treatment of Refractory Livedoid Vasculopathy: A Case Report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2117;
The comprehensive ROCKET phase 3 program will allow robust investigation of the efficacy and long-term safety of rocatinlimab in adults and adolescents with msAD. Afterwards, methotrexate, hydroxychloroquine, pentoxifylline, cyclosporine, enoxaparin treatments administered although the patient
- Enbrel (etanercept) / Pfizer, Amgen
Etanercept therapy in toxic epidermal necrolysis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2033;
Although it is a medical emergency, there is still no effective and well-defined specific treatment. Lack of knowledge and delayed diagnosis are the main reasons for poor outcomes.
- sunitinib / Generic mfg.
Possible Drug-Associated Hidradenitis Suppurativa From Sunitinib In A Patient With Metastatic Renal Cell Carcinoma: A Case Report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2027;
To the best of our knowledge, there is only one article in the literature reporting the association of HS with sunitinib. In their article, Montero-Vilchez and colleagues reported that three patients who were undergoing treatment with sunitinib for RCC had developed new HS lesions or experienced a recurrence of HS.
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
The Double Trouble: Acne and Pyogenic Granuloma in EGFR Inhibitor Treatment (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2008;
They can significantly impact patient quality of life, leading to physical discomfort, psychological distress, and treatment interruptions. The skin adverse reactions during EGFR inhibitors treatment, appear to be mechanism-based linked to the inhibition of EGFR action but the exact pathophysiology remains elusive.
- Clinical Characteristics of Severe Drug Adverse Reactions: A Single-Center Retrospective Study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1988;
Incidence of Cutaneous Adverse Drug Reactions is increasing annually, demanding more clinical attention and research. The mortality rate of adverse drug reactions caused by new drugs is higher, indicating the need for early recognition and management.
- Vectibix (panitumumab) / Amgen
Papulo-pustular rash as a side effect of treatment with epidermal growth factor receptor (EGFR-I) inhibitors: a case report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1987;
Patients are often unable to cope with these side effects, leading to poor adherence to cancer therapy, dose reduction, dose interruption or even discontinuation, and potentially reduced quality of life. The most important conclusion is that skin reactions induced by EGFR inhibitors can be effectively treated in all stages and grades.
- Tremfya (guselkumab) / J&J
Guselkumab-associated bullous pemhigoid in a psoriasis patient: A case report. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1935;
The most important conclusion is that skin reactions induced by EGFR inhibitors can be effectively treated in all stages and grades. This case shows the rare side effect of the development of DBP in a patient being treated with guselkumab.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Comprehensive Review (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1899;
Cyclin-dependent kinase (CDK) -4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are relatively new therapeutic agents that first obtained regulatory approval for hormone receptor 1-positive and human epidermal growth factor receptor 2-negative advanced breast cancer patients who have progressed or relapsed on standard endocrine therapy. Nevertheless, other rare cutaneous adverse events occurred including vitiligo-like lesions, cutaneous lupus erythematosus, bullous skin rash, Stevens
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Exploring the interplay of SAPHO syndrome and follicular occlusion tetrad: an academic investigation into the complex dynamics involving two conditions and an individual (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1795;
The uniqueness of our case lies in the concurrent occurrence of two rare diseases, SAPHO syndrome and follicular occlusion tetrad, which individually represent uncommon clinical entities. Additional research is therefore imperative to elucidate the intricate relationship between SAPHO syndrome and follicular occlusion tetrad.
- | Prolia (denosumab) / Amgen
Journal: Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence. (Pubmed Central) - Aug 5, 2024
The findings suggest an association may exist between lumbar spine BMD change and breast cancer recurrence for patients treated with adjuvant AI. Further research is required to determine whether BMD change can be utilised as a biomarker.
- | Fruzaqla (fruquintinib) / Takeda
Journal, HEOR, Metastases: Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the United States from the payer perspective. (Pubmed Central) - Aug 5, 2024
PMPM costs from the Medicare perspective were greater than the base-case (commercial) ($0.17 vs. $0.07) due to higher incidence of CRC in that population. Fruquintinib is associated with a low budget impact for payers based on proposed thresholds in the US.
- | Prolia (denosumab) / Amgen
Journal: Acceleration of Preexisting Aortic Stenosis After Teriparatide Initiation. (Pubmed Central) - Aug 5, 2024
She underwent parathyroidectomy and was treated with denosumab infusions every 6 months...Chronic exposure of human valvular endothelial cells to parathyroid hormone can trigger endothelial dysfunction and valvular calcification. In patients with preexisting aortic stenosis, coordination of care with cardiology and echocardiographic monitoring while on therapy may be considered.
- | Prolia (denosumab) / Amgen
Journal: Parathyroid Hormone-Related Peptide Secretion From a Pancreatic Neuroendocrine Tumor: A Rare Case Report of Severe Hypercalcemia. (Pubmed Central) - Aug 5, 2024
Although unfit for curative therapy, the patient was treated with fluid replacement, bisphosphonates, calcitonin, and denosumab...This challenging case highlighted the rare but potentially fatal association of pNET with hypercalcemia. Hypercalcemia was the main cause of mortality in an otherwise relatively indolent malignancy.
- | Neulasta (pegfilgrastim) / Roche
Journal: A Case of Revelation Due to Pegfilgrastim. (Pubmed Central) - Aug 5, 2024
Hypercalcemia was the main cause of mortality in an otherwise relatively indolent malignancy. However, the patient shortly developed localized left-sided jaw swelling, and upon further investigation, the granulocyte colony-stimulating
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na (clinicaltrials.gov) - Aug 5, 2024
P2, N=52, Recruiting, Sponsor: St. Jude Children's Research Hospital
However, the patient shortly developed localized left-sided jaw swelling, and upon further investigation, the granulocyte colony-stimulating Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Bone turnover markers during the treatment with romosozumab (Meeting Room 604 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1656;
- Healthcare Resource Use (HRU) and Costs for Patients Living with Osteogenesis Imperfecta (OI): Results from US Retrospective Claims (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1513;
- Disability, functional limitation, and use of anti-fracture drug therapies in a cohort of 3651 U.S. adults with osteogenesis imperfecta (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1488;
- Prolia (denosumab) / Amgen
Updated cost-effectiveness analysis of a 10-year treatment with denosumab versus alendronate in post-menopausal women with osteoporosis in the United States (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1474;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
The Influence of Physical Function on Osteoporosis Treatment: A Study with Romosozumab. (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1472;
- Prolia (denosumab) / Amgen
Subsequent doses of denosumab pose less risk of hypocalcemia than the initial dose does in patients with osteoporosis and chronic kidney disease (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1471;
- Prolia (denosumab) / Amgen
The Effect of Variation of Time Interval of Denosumab (Prolia (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1470;
- The Impact of Osteoporosis Treatment on Trochanteric Hip Fractures with Posterolateral Support Deficiency: A Retrospective Analysis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1468;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Promoted Bone Regeneration of Critical-Size Ulnar Defect Filled with Demineralized Bone Matrix in Non-Human Primates (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1467;
- Treatment Patterns for Medication Related Osteonecrosis of the Jaw (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1466;
- Prolia (denosumab) / Amgen
Comparability of new users of denosumab, oral bisphosphonates and intravenous bisphosphonates in Germany: A retrospective real-world cohort study (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1465;
- zoledronic acid / Generic mfg.
Three-Quarters of Patients Experienced at Least One Symptom After Zoledronate Infusion: Insights from a Single-Center Observational Study (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1463;
- Prolia (denosumab) / Amgen
Denosumab discontinuation rates among older adults in the US versus Canada (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1462;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Effective Management of Osteoporosis Related to Pregnancy and Lactation Using Romosozumab: A Clinical Case Report (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1461;
- Three-dimensional Volumetric Assessment of Fracture Healing after Open Repair of Distal Radius Fracture and Immediate Use of Antiresorptive Agents (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1460;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Improves Areal BMD at the Axial Skeleton but not Areal and Volumetric BMD, Microarchitecture, and Strength at the Peripheral Skeleton in a Real-World Cohort (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1455;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Expected Fracture Outcomes and Associated Costs of Romosozumab Preceding or Following Alendronate in Postmenopausal Women at Very High Fracture Risk in the United States (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1453;
- Effects of different antiresorptive treatment on medication-related osteonecrosis of the jaw in patients undergoing dental procedures: A systematic review and network meta-analysis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1451;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab and denosumab combination therapy in post-menopausal osteoporosis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1450;
- Bone Health in Nursing Home Residents in Germany (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1436;
- Effects of RANKL inhibition on osteotomy healing in a murine model of fibrous dysplasia (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1246;
- Concurrent Treatment with Teriparatide, Estrogen and Thiazides Result in Extremely Large One-Year Gains in BMD (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1165;
- Prolia (denosumab) / Amgen
Outcomes in Cancer Patients on Denosumab 120 mg/month on Utilization of a Unique Pharmacy-driven Home Injection Service Program as Part of a Multi-disciplinary Team (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1127;
- Fracture Rates for Patients Living with Osteogenesis Imperfecta (OI): Real-world Results from US Retrospective Claims (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1088;